Matthew Gentile, MD
Interventional Cardiology · Manitowoc, WINPI 1366551327
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $755 of the $894 with a category attached, or 84.5%. It is spread thinly across 13 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. 2024 is the largest year on record at $482, 3.3 times the $146 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in WI, where the typical reported total is $3,713.
Across 41 payments — averaging $21.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$198
- AstraZeneca$150
- Amgen$96
- E.r. Squibb & Sons, L.L.C.$73
- Boehringer Ingelheim$67
- Pfizer$60
- plus $249 from 7 others
Across 23 payments — averaging $1279.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$17K
- Regeneron$12K
What the payments were for
- Food & beverage$75585%
- Education$13915%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $198 |
| AstraZeneca | 5 | $150 |
| Amgen | 4 | $96 |
| E.r. Squibb & Sons, L.L.C. | 4 | $73 |
| Boehringer Ingelheim | 4 | $67 |
| Pfizer | 3 | $60 |
| Lexicon Pharmaceuticals, Inc. | 3 | $55 |
| Johnson & Johnson | 3 | $53 |
| Novo Nordisk | 2 | $42 |
| Cvrx, Inc. | 2 | $36 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $23 |
| CSL Behring | 1 | $21 |
| Biotronik Inc. | 1 | $18 |
How this compares
$894 in reported general payments places this provider in the 20th percentile of 118 interventional cardiology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 388 | $364,817 |
| XareltoRivaroxaban | 141 | $153,115 |
| JardianceEmpagliflozin | 99 | $95,006 |
| EntrestoSacubitril/Valsartan | 83 | $81,471 |
| BrilintaTicagrelor | 69 | $53,771 |
| FarxigaDapagliflozin Propanediol | 30 | $26,594 |
| Repatha SureclickEvolocumab | 30 | $25,522 |
| Digoxin | 266 | $6,392 |
| Metoprolol Succinate | 412 | $6,300 |
| Diltiazem 24hr ErDiltiazem Hcl | 130 | $3,468 |
| Atorvastatin Calcium | 276 | $3,067 |
| Potassium Chloride | 112 | $2,870 |
| Rosuvastatin Calcium | 222 | $2,819 |
| Losartan Potassium | 245 | $2,760 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 111 | $2,679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $60 | $364,817388 claims |
| Johnson & JohnsonXarelto | $53 | $153,115141 claims |
| Boehringer IngelheimJardiance | $67 | $95,00699 claims |
| NovartisEntresto | $198 | $81,47183 claims |
| AstraZenecaBrilinta, Farxiga | $150 | $80,36699 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 118 interventional cardiology providers in Wisconsin.
Other interventional cardiology in Manitowoc
- Michael RosenbergManitowoc$111K
- Michael SalingerMilwaukee$216K
- Arun KalyanasundaramMarshfield$201K
- Tanvir BajwaMilwaukee$106K
- Suhail AllaqabandMilwaukee$88K
- Saif AnwaruddinMilwaukee$80K
- Raaid MuseitifKenosha$71K
- Iyad AzzamMilwaukee$60K
- Mark HoffmannWausau$52K
- Montoya TaylorMilwaukee$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.